echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Ganciclovir Sodium for injection of Puli pharmaceutical was approved for listing in Cyprus

    Ganciclovir Sodium for injection of Puli pharmaceutical was approved for listing in Cyprus

    • Last Update: 2020-02-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On February 4, Puli pharmaceutical announced that the company had recently received a notice that the registration application of 500mg Ganciclovir Sodium for injection submitted to the Cyprus pharmaceutical regulatory authority had been approved Ganciclovir is a derivative of guanine nucleoside Similar to acyclovir, ganciclovir is the first effective drug for human cytomegalovirus It can not only inhibit all herpesviruses, but also block the lesions of normal zonal lymphocytes caused by EB virus It was first synthesized by Julien Verheyden and John Martin of syntex Research (now Roche) in 1980 The mechanism of ganciclovir inhibiting the synthesis of viral DNA lies in: competitive inhibition of the binding of deoxyguanosine's trivalent phosphate to DNA polymerase, and the binding of trioxyguanosine's trivalent nitrate to viral DNA eventually leads to the stop of DNA elongation.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.